ALXO FY 2024 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$112M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$142M

Net Income

-$135M

EPS (Diluted)

$-2.58

Cash Flow

Operating Cash Flow

-$122M

Free Cash Flow

-$122M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$148M

Total Liabilities

$34M

Stockholders' Equity

$114M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$142M	-$170M	+16.3%
Net Income	-$135M	-$161M	+16.1%